(Monday, November 3, 2014) - The following are soundbites from Maria Croyle, R.Ph., Ph.D., from the University of Texas at Austin College of Pharmacy, regarding a nasal vaccine in development that has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.
This work is being presented at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the worldâ€™s largest pharmaceutical sciences meeting, in San Diego, November 2 to 6.
Maria Croyle, R.Ph., Ph.D. and Kristina Jonsson-Schmunk, from the University of Texas at Austin bites:
SOUNDBITE #1 (Croyle)
THE MAIN ADVANTAGE OF OUR VACCINE PLATFORM OVER THE OTHERS IN CLINICAL TESTING IS THE LONG-LASTING PROTECTION AFTER A SINGLE INTRANASAL DOSE. MOREOVER, THE NASAL SPRAY IMMUNIZATION METHOD IS MORE ATTRACTIVE THAN A NEEDLE VACCINE GIVEN THE COSTS ASSOCIATED WITH SYRINGE DISTRIBUTION AND SAFETY (:15)
SOUNDBITE #2 (Jonsson-Schmunk)
ALTHOUGH PROGRESS HAS BEEN MADE IN UNDERSTANDING THE VIRUSâ€™ BIOLOGY, NO LICENSED VACCINES OR TREATMENTS CURRENTLY EXIST. THERE IS A DESPERATE NEED FOR A VACCINE THAT NOT ONLY PREVENTS THE CONTINUED TRANSMISSION FROM PERSON TO PERSON, BUT ALSO AIDS IN CONTROLLING FUTURE INCIDENCES (:15)